Bovine Immunodeficiency Virus: Veterinary Reference

Overview and Taxonomic Classification of Bovine Immunodeficiency Virus

Historical Context and Discovery

The Bovine Immunodeficiency Virus (BIV) represents a significant, albeit historically understudied, member of the lentivirus genus within the Retroviridae family. First identified in the late 20th century, BIV's discovery emerged from the broader investigation of retroviral diseases in cattle, a field long dominated by the economically devastating Bovine Leukemia Virus (BLV). The initial isolation of BIV, originally termed the "bovine immunodeficiency-like virus," was documented from a serendipitous finding in a dairy cow in the United States that presented with a constellation of clinical signs including lymphocytosis, progressive weakness, and emaciation [5]. This index case, described in the foundational literature, did not conform to the typical pathology of enzootic bovine leukosis, prompting a detailed virological investigation that ultimately revealed a novel lentivirus [5].

The taxonomic journey of BIV has been intricate, reflecting its genetic and structural relationship to other well-characterized lentiviruses, most notably the Human Immunodeficiency Virus (HIV) and Feline Immunodeficiency Virus (FIV) [1, 5]. Early phylogenetic analyses placed BIV as a distinct but related outlier to the primate and feline lentiviruses, a positioning that has been refined through advancements in molecular virology. The nomenclature has shifted from "bovine immunodeficiency-like virus" to the more definitive "bovine immunodeficiency virus," a change that underscores its established role as a true lentivirus capable of inducing a protracted, progressive immunopathology in its natural bovine host [2, 5]. This reclassification is not merely semantic; it aligns BIV with the broader understanding of lentiviral pathogenesis, which is characterized by long latency periods, persistent infection, and eventual immune system collapse.

Taxonomic Position and Virion Structure

BIV is unequivocally classified within the family Retroviridae, subfamily Orthoretrovirinae, and genus Lentivirus. This taxonomic assignment is supported by its genetic organization, virion morphology, and replication strategy, which are hallmarks of the lentivirus group. Within the lentivirus genus, BIV forms a distinct clade, often clustering phylogenetically with viruses like the Jembrana disease virus of cattle and the caprine arthritis-encephalitis virus, reflecting a shared evolutionary lineage adapted to ungulate hosts [1, 5].

The mature BIV virion is a spherical, enveloped particle approximately 80–130 nm in diameter. Its morphology is characteristic of lentiviruses, featuring a dense, cone-shaped or cylindrical nucleocapsid core. This core is composed primarily of the major capsid protein, p26, which serves as a critical structural component and a primary target for serological diagnostics [2]. Surrounding the core is a lipid bilayer envelope derived from the host cell membrane, which is studded with viral glycoproteins. The surface glycoprotein, gp100 (or SU), is responsible for attachment to the host cell receptor, while the transmembrane glycoprotein, gp45 (or TM), facilitates membrane fusion during viral entry [2]. The intricate architecture of these envelope proteins dictates the virus's tropism for specific cell types, predominantly cells of the monocyte/macrophage lineage and lymphocytes.

Genomic Organization and Molecular Biology

The BIV genome is a positive-sense, single-stranded RNA molecule, approximately 9.0 to 9.5 kilobases in length. Its genomic structure is classic for a complex lentivirus, containing the essential retroviral genes gag, pol, and env, flanked by long terminal repeats (LTRs) that regulate viral transcription and integration. The gag gene encodes the structural polyprotein precursor, which is cleaved by the viral protease to yield the matrix (MA), capsid (CA, p26), and nucleocapsid (NC) proteins. The pol gene encodes the enzymatic machinery of the virus, including the protease (PR), reverse transcriptase (RT), and integrase (IN). The env gene encodes the envelope glycoproteins, which are synthesized as a precursor (gp145) and subsequently cleaved into the surface (SU, gp100) and transmembrane (TM, gp45) subunits [2].

In addition to these canonical genes, BIV possesses a suite of accessory genes that are critical for viral replication, persistence, and pathogenesis. These include vif, tat, rev, and vpy, genes that share functional homology with their counterparts in HIV and other lentiviruses [5]. The vif (viral infectivity factor) gene product is essential for productive infection of non-dividing cells, counteracting host restriction factors. The tat (transactivator of transcription) gene encodes a potent transcriptional activator that binds to the LTR to significantly enhance viral gene expression. The rev (regulator of expression of virion proteins) gene controls the nuclear export of unspliced and partially spliced viral mRNAs, a crucial step in the switch from early to late viral gene expression. The presence of vpy is a distinctive feature of BIV, though its precise function in the bovine host remains an area of active investigation. The regulatory complexity conferred by these accessory genes allows BIV to establish a state of persistent, low-level replication that can evade the host immune system for extended periods, a hallmark of lentiviral infection [5].

Antigenic Properties and Serological Distinction

The antigenic profile of BIV is critical for its accurate serological detection and differentiation from other bovine retroviruses, particularly the closely monitored Bovine Leukemia Virus (BLV). The major antigenic targets for serodiagnosis are the p26 capsid protein and the transmembrane envelope protein (gp45) . The p26 protein is highly immunogenic and well-conserved among BIV isolates, making it a robust target for antibody detection. Studies have demonstrated that recombinant p26 protein-based Western blot assays show 100% concordance with reference Western blots using whole virus, confirming its reliability as a diagnostic antigen [2].

Crucially, sera from cattle infected with other retroviruses, such as Bovine Syncytial Virus or Bovine Leukemia Virus, do not cross-react with BIV-specific recombinant proteins, confirming the high serological specificity of these assays [2]. This antigenic distinction is vital for epidemiological surveillance, as mixed infections with BLV and BIV are known to occur in cattle populations [4]. The transmembrane protein (tTM), while also immunogenic, has shown a slightly different diagnostic profile. In some studies, the tTM-based Western blot identified a small number of BIV-positive sera that were negative by both the p26 recombinant and whole-virus-based Western blots, suggesting that the tTM antigen may detect seroconversion at a different stage of infection or capture a broader spectrum of antibody responses [2]. This finding underscores the potential utility of a multi-antigen approach to maximize diagnostic sensitivity.

Host Range, Transmission, and Epidemiological Context

BIV has a narrow host range, with natural infection occurring predominantly in domestic cattle (Bos taurus). Experimental infection has been achieved in other species, such as rabbits and sheep, but these models do not fully recapitulate the natural disease course. The virus exhibits a cellular tropism for cells of the immune system, including monocytes, macrophages, and B and T lymphocytes, a characteristic that directly underpins its immunosuppressive effects [5].

The transmission dynamics of BIV are still being elucidated, but they share similarities with other lentiviruses and bovine retroviruses. Vertical transmission from dam to calf, likely via ingestion of colostrum or milk, is considered a significant route of infection. The question of whether BIV in milk is inactivated by standard pasteurization processes has been investigated, with early studies suggesting that pasteurization may not fully eliminate the virus [3]. Horizontal transmission via iatrogenic routes, such as the use of contaminated needles, surgical instruments, or dehorning and tattooing equipment, is also a potential pathway. The role of insect vectors, a topic of intense research for BLV, remains uncertain for BIV transmission [1]. The economic consequences of BIV infection, while not as starkly defined as for BLV, are recognized to include subclinical impacts on immune function, potentially leading to increased susceptibility to secondary infections, reduced milk production, and overall diminished herd health [5].

Diagnostic Implications and Veterinary Significance

From a veterinary diagnostic standpoint, BIV has historically been a neglected pathogen. It is not currently a notifiable disease to the World Organisation for Animal Health (WOAH), and routine surveillance is not widely practiced outside of research settings. However, the recognition of BIV as a contributing factor in the "wasting disease" complex in cattle and its potential role as an immunosuppressive agent that could exacerbate the pathology of other infections is growing. The development of reliable serological tools, such as the recombinant p26 and tTM Western blot assays and the potential for ELISA-based platforms, is paving the way for more systematic epidemiological studies [2, 4].

The detection of BIV genetic material in cattle populations in various countries, including recent reports from Ukraine, indicates that the virus is globally distributed, albeit at variable prevalence rates [4]. The frequent co-detection of BIV with BLV suggests that these retroviruses may interact within the host, potentially leading to more severe immunopathology than either virus alone [4]. This associative nature of infection highlights a critical gap in current veterinary practice: the need to consider BIV as a differential diagnosis in herds with unexplained immunosuppression, chronic ill-thrift, or increased incidence of opportunistic infections that cannot be solely attributed to BLV or Bovine Viral Diarrhea Virus (BVDV). As the international community moves toward improved biosecurity and disease control in livestock, a comprehensive understanding of BIV's taxonomy, molecular biology, and epidemiology will become increasingly essential for managing the full spectrum of infectious diseases affecting cattle worldwide.

Molecular Pathogenesis of Bovine Immunodeficiency Virus

The molecular pathogenesis of Bovine Immunodeficiency Virus (BIV) represents a complex interplay between a lentiviral pathogen and the bovine host, culminating in a progressive, albeit often subclinical, immunodysfunction. Understanding this process at a molecular and cellular level is critical for elucidating the virus’s impact on herd health, its potential role as a co-factor in other bovine diseases, and its utility as a comparative model for human lentiviral infections such as HIV. BIV, a member of the Retroviridae family, genus Lentivirus, shares significant structural and genetic homology with other immunodeficiency-inducing lentiviruses, including Feline Immunodeficiency Virus (FIV) and Human Immunodeficiency Virus (HIV) [6, 8, 14]. This section provides an exhaustive analysis of the molecular mechanisms governing BIV entry, replication, cellular tropism, immune evasion, and the consequent pathological sequelae that define its pathogenesis.

Genomic Organization and Structural Basis of Pathogenesis

The BIV genome, approximately 8.9 kb in length, is a complex retrovirus encoding the canonical structural and enzymatic proteins, Gag, Pol, and Env, alongside several regulatory and accessory genes that are pivotal for its pathogenic potential [5]. The gag gene encodes the precursor protein that is cleaved into the matrix (MA), capsid (CA, p26), and nucleocapsid (NC) proteins. The p26 capsid protein is a major immunodominant antigen and serves as the primary target for serological diagnosis via Western blot and ELISA-based assays [2]. The pol gene encodes the viral enzymes: reverse transcriptase (RT), integrase (IN), and protease (PR). The env gene encodes the surface (SU, gp100) and transmembrane (TM, gp45) glycoproteins, which are critical for receptor binding and membrane fusion. The TM protein, particularly its ectodomain, contains conserved epitopes that are recognized by the host immune system and have been exploited for diagnostic purposes using recombinant proteins [2].

A defining feature of BIV’s molecular complexity is its repertoire of regulatory and accessory genes, including tat, rev, vif, vpy, vpr, and vpx. These genes are essential for modulating viral gene expression, enhancing viral replication, and counteracting host intrinsic immune defenses. The tat gene product is a potent transactivator of viral transcription, binding to the transactivation response (TAR) element at the 5’ end of viral RNA to recruit cellular cyclin T1 and CDK9, thereby promoting RNA polymerase II processivity. The rev protein facilitates the nuclear export of unspliced and singly-spliced viral mRNAs, a critical step for the production of structural proteins. The accessory proteins Vif, Vpy, Vpr, and Vpx are less well-characterized in BIV compared to HIV, but they are hypothesized to play analogous roles in counteracting host restriction factors, such as APOBEC3 proteins, and in modulating the cell cycle to create a favorable environment for viral replication [5].

Viral Entry, Cellular Tropism, and Receptor Usage

The initial step in BIV pathogenesis is the attachment and entry into susceptible host cells. The viral envelope glycoprotein (Env) mediates this process. The SU glycoprotein (gp100) binds to a specific cellular receptor, while the TM glycoprotein (gp45) facilitates the fusion of the viral and cellular membranes. Unlike HIV, which uses CD4 as its primary receptor, the primary receptor for BIV has not been definitively identified but is believed to be a chemokine receptor, likely CXCR4 or a related molecule. This is supported by the virus’s tropism for cells of the monocyte/macrophage lineage and, to a lesser extent, lymphocytes. BIV exhibits a broad in vivo tropism, with viral nucleic acid and antigens detected in a variety of tissues, including peripheral blood mononuclear cells (PBMCs), lymph nodes, spleen, lung, and brain. Within the PBMC population, monocytes and macrophages are the primary targets, serving as a long-lived viral reservoir. This tropism is a hallmark of lentiviral pathogenesis, as infected macrophages can disseminate the virus throughout the body while resisting the cytopathic effects that often kill infected T lymphocytes. The ability of BIV to infect cells of the central nervous system, leading to meningoencephalitis in some cases, is a direct consequence of its tropism for perivascular macrophages and microglial cells.

Molecular Mechanisms of Immune Evasion and Persistence

BIV has evolved sophisticated molecular strategies to evade the host immune response, establishing a lifelong persistent infection. A primary mechanism is the establishment of viral latency. Following integration into the host genome as a provirus, BIV can enter a state of transcriptional silence, particularly in resting memory T cells and tissue macrophages. This latent reservoir is invisible to the host immune system and impervious to antiviral drugs, making eradication impossible. The molecular switch between latency and productive replication is governed by a complex interplay of cellular transcription factors and the viral Tat protein. Cellular activation signals, such as those triggered by co-infections or inflammation, can reactivate latent provirus, leading to bursts of viral replication.

Another critical evasion strategy is antigenic variation. The BIV env gene, particularly the hypervariable regions of the SU glycoprotein, is subject to a high rate of mutation due to the error-prone nature of reverse transcriptase. This generates a swarm of closely related but antigenically distinct viral variants, known as quasispecies. This genetic diversity allows the virus to escape neutralizing antibodies and cytotoxic T lymphocyte (CTL) responses. The constant selection pressure from the host immune system drives the evolution of escape mutants, ensuring the persistence of the infection. Furthermore, BIV, like other lentiviruses, can downregulate the expression of major histocompatibility complex (MHC) class I molecules on the surface of infected cells, thereby reducing the recognition and killing of infected cells by CTLs. The accessory protein Vif is also crucial for evading the host restriction factor APOBEC3, a cytidine deaminase that can hypermutate the viral genome during reverse transcription, rendering it non-infectious. BIV Vif counteracts this by targeting APOBEC3 for proteasomal degradation.

Pathological Sequelae: From Molecular Dysregulation to Clinical Disease

The molecular pathogenesis of BIV culminates in a spectrum of pathological changes, most notably a progressive immunodeficiency. The hallmark of this immunodeficiency is the depletion and dysfunction of CD4+ T lymphocytes, mirroring the pathogenesis of HIV and FIV [8, 12]. Although the precise mechanism of T cell depletion in BIV infection is not fully elucidated, it likely involves a combination of direct viral cytopathicity, syncytia formation mediated by the Env glycoprotein, and immune-mediated destruction of infected cells. The chronic immune activation, driven by persistent viral replication, leads to the exhaustion and eventual apoptosis of uninfected bystander T cells. This results in a state of immunosuppression, characterized by lymphopenia, particularly a reduction in the CD4+/CD8+ T cell ratio, and impaired lymphocyte proliferative responses.

This acquired immunodeficiency predisposes BIV-infected cattle to a range of secondary infections and opportunistic diseases. BIV has been implicated as a contributing factor in the pathogenesis of other economically significant bovine diseases, such as bovine leukemia virus (BLV)-induced enzootic bovine leukosis and bovine viral diarrhea virus (BVDV) infections [1, 7, 9-11, 13]. The immunosuppression caused by BIV can exacerbate the clinical course of these co-infections, leading to more severe disease, prolonged viremia, and increased viral shedding. For example, BIV co-infection may accelerate the progression of BLV from a benign lymphocytosis to a malignant lymphoma. This synergistic interaction is a critical area of research, as it suggests that BIV, even in the absence of overt clinical signs, can have a significant impact on herd health and productivity by acting as a co-morbidity factor [4]. The virus has also been associated with neurological disease, specifically a non-suppurative meningoencephalitis, characterized by perivascular cuffing with mononuclear cells and gliosis. The molecular basis for this neurovirulence is not fully understood but is likely related to the virus’s ability to infect and replicate within microglial cells and perivascular macrophages, leading to the release of neurotoxic cytokines and chemokines.

Comparative Pathogenesis and Implications for Disease Control

The molecular pathogenesis of BIV offers a valuable comparative model for understanding human lentiviral diseases, particularly HIV-1. The similarities in genomic organization, cellular tropism, mechanisms of immune evasion, and the induction of a chronic, progressive immunodeficiency make BIV infection in cattle a relevant large-animal model for studying HIV pathogenesis, vaccine development, and antiviral therapies. The World Organisation for Animal Health (WOAH) recognizes the importance of understanding such retroviral infections in livestock, as they can impact international trade and animal health. The Food and Agriculture Organization (FAO) also emphasizes the need for robust surveillance and control programs for livestock diseases that can compromise food security. While BIV is not considered a major zoonotic pathogen like HIV, its study provides critical insights into the fundamental biology of lentiviruses. The detection of BIV genetic material in cattle populations in countries like Ukraine underscores the global distribution of this virus and the need for continued surveillance [4]. The development of sensitive and specific diagnostic tools, such as the recombinant protein-based Western blot assays for detecting anti-p26 and anti-tTM antibodies, is crucial for understanding the true prevalence and impact of BIV infection [2]. Ultimately, a deep molecular understanding of BIV pathogenesis is essential for developing effective control strategies, including the potential for vaccines or antiviral interventions, and for mitigating the subclinical economic losses associated with this persistent infection.

Epidemiology of Bovine Immunodeficiency Virus Infection in Cattle

Bovine immunodeficiency virus (BIV), a lentivirus within the family Retroviridae, represents a pathogen of considerable yet often underestimated significance in global cattle health. Since its initial isolation from a dairy cow with persistent lymphocytosis in Louisiana in 1969, a case that also harbored concurrent bovine leukemia virus (BLV) infection [5], the epidemiology of BIV has been characterized by a perplexing dichotomy between widespread serological evidence and a frequently subclinical presentation. Comprehensive epidemiological understanding is essential for assessing the true economic burden of BIV, designing rational control strategies, and differentiating its impact from more overtly pathogenic bovine retroviruses such as BLV.

Global Distribution and Seroprevalence

The precise global distribution of BIV remains incompletely mapped, largely owing to the historical lack of standardized, widely available diagnostic reagents and the absence of mandatory surveillance programs. However, serological surveys employing a variety of detection methods, including Western blotting (WB), enzyme-linked immunosorbent assay (ELISA), and polymerase chain reaction (PCR), have revealed a remarkably broad geographic footprint. Early seroepidemiological work in the United States, utilizing recombinant protein-based Western blot assays targeting the major capsid protein p26 and the transmembrane envelope protein (tTM), demonstrated infection rates that varied from zero to over 30% in some herds, with an overall animal-level prevalence of approximately 3.8% in a convenience sample of 105 sera [2]. This work underscored a critical epidemiological principle: diagnostic methodology profoundly influences apparent prevalence. The tTM-based Western blot identified four additional seropositive animals that were missed by both the p26-based WB and a reference WB using whole-virus antigen, suggesting that reliance on a single antigenic target could underestimate true infection rates [2].

More recently, the detection of BIV genetic material in Ukraine has extended the known range of the virus and provided molecular confirmation of its circulation in Eastern European livestock [4]. This finding, achieved through PCR-based screening, is particularly noteworthy as it also documented the associative nature of infection with other retroviruses, specifically bovine leukemia virus and bovine foamy virus [4]. This clustering of retroviral infections within individual animals and herds is a recurring epidemiological theme. The phenomenon raises critical questions about potential synergistic immunological interactions, shared transmission risk factors, or the possibility that one infection may facilitate the establishment of another. Such co-infection dynamics are likely to modulate the clinical expression of BIV, potentially exacerbating immunosuppression or altering the progression of lymphoproliferative disorders typically attributed to BLV alone.

The seroprevalence data must be interpreted with caution. The original sentinel case occurred in a cow with concurrent BLV infection, and early studies often relied on samples from animals with suspected retroviral disease, introducing selection bias [5]. Furthermore, the antibody response to BIV can be weak and intermittent, leading to false-negative serological results in infected animals [2, 5]. This diagnostic challenge means that cross-sectional serosurveys likely underestimate the true cumulative incidence of infection, particularly in herds with low force of infection or in animals that were infected long before sampling.

Transmission Dynamics: Routes, Reservoirs, and Risk Factors

The mechanisms by which BIV perpetuates within and between cattle populations are complex and involve both horizontal and vertical pathways, though the relative contribution of each remains an active area of investigation. The epidemiological parallels drawn from the better-studied BLV are instructive but incomplete, as BIV appears to be less efficiently transmitted [1, 10].

Horizontal Transmission: Iatrogenic transmission is considered a major driver of BIV spread, mirroring the epidemiology of BLV. The use of contaminated needles, surgical instruments (e.g., dehorners, tattoo pliers, castration knives), and, critically, the administration of blood-contaminated biological products (such as whole blood for transfusion or contaminated colostrum) are established risk factors [5, 10]. The association between BIV infection and herd-level management practices has been modeled using mixed-effects logistic regression, which accounts for the inherent clustering of infection within herds [5]. These analyses confirm that procedures breaching skin or mucosal barriers significantly increase the odds of seropositivity.

A particularly contentious and biologically significant question is the role of vector-mediated transmission. Blood-sucking arthropods, including tabanid flies (Tabanidae spp.), stable flies (Stomoxys calcitrans), and ixodid ticks, are mechanically capable of transferring blood-borne pathogens between animals [1]. Given that BIV, like BLV, is a cell-associated virus present in circulating lymphocytes, interrupted feeding by hematophagous insects could theoretically deposit infected cells onto a new host. While empirical evidence for BIV transmission by vectors is sparse compared to BLV, the epidemiological context of BIV, often occurring in herds with high vector pressure and concurrent BLV infection, supports the plausibility of this route [1]. The potential for ticks, whose feeding duration is prolonged, to serve as more efficient mechanical vectors than flies requires further investigation. This vector hypothesis is critical for understanding the maintenance of BIV in grazing systems where iatrogenic exposures are minimized.

Vertical and Perinatal Transmission: Evidence for vertical transmission of BIV exists but suggests it is not a highly efficient route. The virus can be detected in milk, and the ingestion of infected colostrum or milk by neonatal calves represents a plausible mechanism of postpartum infection [3]. A landmark bioassay study directly addressed this risk by evaluating the inactivation of BIV in milk by commercial pasteurization. The study demonstrated that standard high-temperature short-time (HTST) pasteurization effectively inactivates BIV, rendering milk safe for calf feeding [3]. This finding has profound implications for herd management: in operations that feed unpasteurized waste milk from seropositive cows, the risk of transmitting the infection to replacement heifers is elevated. In utero transmission has also been inferred from the detection of proviral DNA in fetal tissues, but the rate of congenital infection appears low [5].

Spatial Epidemiology, Clustering, and Herd-Level Dynamics

The epidemiology of BIV exhibits pronounced spatial heterogeneity, consistent with the behavior of a slowly spreading, horizontally transmitted retrovirus. Infection tends to cluster within herds, and within regions, rather than being uniformly distributed. This clustering pattern is analogous to that observed in enzootic bovine leukosis (EBL) control programs, where the last pockets of infection are often geographically restricted and linked to specific management deficiencies [11]. For BIV, the presence of a "superspreader" animal, a cow with particularly high proviral load or prolonged viremia, could disproportionately contribute to within-herd transmission. The statistical power required to detect such clustering and to identify risk factors at the herd level is considerable, demanding careful study design that accounts for the non-independence of observations (i.e., the intraclass correlation coefficient) [5].

The recent molecular detection of BIV in Ukraine [4] also signals the potential for spatial expansion. The virus may be more prevalent in regions where diagnostic surveillance for retroviruses is rudimentary or non-existent. The ecological niche of BIV may overlap with regions of high BLV seroprevalence, such as those documented in Colombia (67.7% herd-level BLV prevalence) or the persistent clusters in Italy [10, 11]. In such environments, the combined burden of multiple retroviral infections could have additive or synergistic immunosuppressive effects, predisposing animals to secondary bacterial infections, mastitis, or poor vaccine responses, all of which are difficult to attribute to a single agent in field settings.

Methodological Challenges and Implications for Epidemiological Inference

A fundamental barrier to a precise understanding of BIV epidemiology remains the diagnostic tools available. The development of recombinant protein-based Western blotting represented a major advance, providing specificity superior to whole-virus antigen preparations and allowing differentiation from other bovine retroviruses [2]. However, WB is labor-intensive, subjective in interpretation, and difficult to standardize across large surveillance programs. The lack of a commercial, high-throughput, validated ELISA suitable for large-scale serosurveillance is a critical gap. Furthermore, the detection of BIV proviral DNA by PCR, while sensitive, is subject to sampling variation due to fluctuating cell-associated viremia.

These diagnostic limitations directly distort epidemiological parameters. Apparent prevalence is a function of test sensitivity; as such, the true prevalence of BIV infection in most populations is likely higher than reported. The consequence is that risk-factor analyses based on serological data may underestimate the strength of associations, potentially leading to the erroneous dismissal of important management interventions. The development and validation of standardized control sera, as has been accomplished for bovine viral diarrhea virus (BVDV) diagnostics, would be a transformative step for BIV epidemiology, enabling inter-laboratory comparisons and robust meta-analyses [9].

In the absence of a national eradication program for BIV, unlike the mandatory programs for BVDV in Ireland [7] or EBL in Italy [11], the epidemiology of BIV is largely shaped by voluntary management decisions and the inadvertent consequences of other disease control activities (e.g., reuse of needles for BLV testing). The virus persists as a silent comorbidity, its epidemiological footprint expanding and contracting in response to the dynamics of the cattle trade, vector abundance, and the immunological status of the host population. The field awaits the kind of structured, population-based surveillance that would allow us to move from a patchwork of serosurveys to a comprehensive, dynamic spatial model of infection risk.

Diagnostics and Laboratory Detection of Bovine Immunodeficiency Virus

The diagnosis of Bovine Immunodeficiency Virus (BIV) infection presents a formidable challenge in veterinary virology, largely due to the virus’s insidious nature, its propensity for lifelong latency, and the persistent lack of a widely standardized, commercially available diagnostic platform. Unlike its better-characterized counterparts, Bovine Leukemia Virus (BLV) or Bovine Viral Diarrhea Virus (BVDV), BIV has remained a neglected pathogen, relegated to the periphery of routine veterinary surveillance. This diagnostic lacuna is a direct consequence of the virus’s complex biology and the historical reliance on research-grade assays that have not been translated into scalable, field-deployable tests. A thorough understanding of the available diagnostic modalities, their inherent limitations, and the emerging molecular strategies is essential for any comprehensive veterinary reference on this subject.

The Diagnostic Imperative: Challenges and Context

The fundamental obstacle to routine BIV detection lies in the virus’s low-level, cell-associated viremia and its integration into the host genome as a latent provirus. This biological reality renders traditional virus isolation, while historically valuable, an impractical and insensitive tool for large-scale surveillance. In early studies, bioassay, the inoculation of suspect material into indicator calves, was employed to assess infectivity, for instance, in evaluating the stability of BIV in milk following pasteurization [3]. This approach, however, is prohibitively expensive, time-consuming (requiring weeks to months for seroconversion), and subject to significant ethical and logistical constraints. Furthermore, the presence of maternally derived antibodies in young calves can confound serological results, while the intermittent nature of antigen expression in latently infected adults means that a single negative test does not rule out infection [2, 5].

The diagnostic landscape is further complicated by the virus’s genetic diversity and its association with other common retroviruses, particularly BLV. As documented in field studies from Ukraine, the genetic material of BIV and Bovine Foamy Virus (BFV) was detected alongside BLV in cattle, suggesting a frequent pattern of co-infection [4]. This syndemic reality necessitates diagnostic tools with exquisite specificity to avoid cross-reactivity with related retroviral antigens, a challenge that has historically plagued serological development. The economic impact of these infections, ranging from reduced milk production and fertility to increased susceptibility to secondary diseases, underscores the urgent need for reliable detection methods that can inform herd management decisions [1, 5].

Serological Detection: The Foundation of BIV Diagnosis

For decades, the cornerstone of BIV diagnostics has been the detection of virus-specific antibodies in serum, leveraging the host’s humoral immune response as a surrogate marker of infection. The most robust serological platform developed to date remains the Western blot (WB) assay, refined by researchers using recombinant proteins derived from the viral capsid (p26) and the transmembrane envelope protein (tTM) [2]. This approach marked a significant departure from earlier WB methods that relied on crude, cell-culture-derived virions, which were hampered by batch-to-batch variability and the presence of cellular contaminants that could produce non-specific reactions.

Recombinant Protein-Based Western Blot

The development of a recombinant-protein WB involved the expression of a 120-amino-acid polypeptide from the tTM region and the full-length major capsid protein p26 using baculovirus vectors [2]. This strategy allowed for the production of highly purified, standardized antigens. The diagnostic performance of these recombinant proteins was rigorously evaluated against a reference WB using whole-virus lysate. When the p26 fusion protein was used as the test antigen, a 100% concordance was observed with the reference assay. This finding underscored the immunodominance of the capsid protein and its reliability as a diagnostic target. However, the tTM-based WB, while specific (showing no cross-reactivity with antisera to Bovine Syncytial Virus or BLV), identified four additional BIV-positive sera that had been classified as negative by both the p26-based WB and the reference assay, resulting in a lower concordance of 96.2% [2]. This discrepancy highlights a critical nuance: the tTM antigen may detect antibodies that appear earlier or persist longer in the course of infection, suggesting that a multi-antigen approach is necessary for maximum diagnostic sensitivity. The study established that both p26 and tTM are valuable, complementary targets, and that reliance on a single antigen, particularly in the context of genetic drift or variable host immune responses, risks false-negative results.

The Absence of a Validated Commercial ELISA

Despite the success of the research-grade Western blot, the field has been conspicuously bereft of a validated, commercially available enzyme-linked immunosorbent assay (ELISA) for BIV. This stands in stark contrast to other bovine retroviruses; for example, BLV diagnosis is routinely performed using highly standardized ELISAs, which have been instrumental in national eradication programs [10, 11]. The absence of a BIV ELISA is not for lack of trying. The inherent difficulty lies in the virus's low antigenic stimulation during latency and the potential for high background reactivity in bovine sera. Researchers have noted that while indirect ELISA formats could be developed using the same recombinant p26 and tTM proteins, the transition from a labor-intensive Western blot to a rapid, high-throughput ELISA requires overcoming challenges related to antigen coating efficiency, blocking of non-specific binding, and establishing statistically robust cut-off values [2, 5]. Recent work on similar retroviral diagnostics in other species, such as the development of the FIVCHECK Ab ELISA for cats, demonstrates that meticulous optimization, including the use of Youden’s index and ROC curve analysis, is essential to achieve acceptable sensitivity and specificity [17]. For BIV, such comprehensive validation studies on a commercial scale have yet to be published.

Complementing the effort to develop custom serological tests is the recognition that standard clinical pathology may offer indirect diagnostic clues. In feline immunodeficiency virus (FIV) infections, which share a lentiviral pathogenesis with BIV, affected animals often present with hyperglobulinemia, hypoalbuminemia, and elevated erythrocyte sedimentation rates [6, 8]. Similarly, in BIV-infected cattle, clinicopathological abnormalities, such as lymphopenia, reduced CD4+/CD8+ ratios, and altered albumin-to-globulin ratios, have been anecdotally reported but have not been systematically validated as screening tools [5]. These changes are non-specific but can serve as "diagnostic triggers" to prompt more specific BIV testing in a research setting [8].

Molecular Detection: PCR and Metatranscriptomic Approaches

The advent of polymerase chain reaction (PCR) has revolutionized the detection of slow or unculturable viruses, and BIV is no exception. Molecular methods offer the distinct advantage of detecting proviral DNA integrated into the host genome, thereby circumventing the problems of transient viremia and latent infection that plague serology and virus isolation.

Conventional and Quantitative PCR

The first molecular detection of BIV in field samples from Ukraine was accomplished using nested reverse-transcription PCR (RT-PCR) targeting the pol gene, which encodes the viral reverse transcriptase and is highly conserved among lentiviruses [4]. This approach successfully amplified BIV-specific sequences from peripheral blood leukocytes, confirming the presence of the virus in cattle that were otherwise clinically unremarkable. The choice of the pol gene as a target is strategic; it is less prone to the genetic hypervariability seen in the env gene, making it a robust target for detecting a wide range of viral strains. The relative sensitivity of this nested PCR was not explicitly quantified in the Ukrainian study, but the ability to detect provirus in animals with low or undetectable antibody titers positions PCR as a superior tool for identifying early-stage or immunotolerant infections.

Quantitative real-time PCR (qPCR and RT-qPCR) represents the next frontier for BIV diagnostics. By incorporating fluorescent probes or intercalating dyes like SYBR Green I, these assays can not only detect the presence of viral nucleic acid but also quantify the viral load. Drawing from successful models developed for other bovine RNA viruses, such as Bovine Ephemeral Fever Virus (BEFV), one can envision a SYBR Green I–based RT-qPCR for BIV that targets the gag or pol gene [18]. Such an assay would enable kinetic profiling of viral replication, allowing researchers to correlate viral load with clinical stages of disease or with the efficacy of potential antiviral interventions. The precision of these assays is typically very high, with intra- and inter-assay coefficients of variation below 2% [18], making them suitable for longitudinal studies. The major challenge remains the design of primers that can tolerate the genetic variability of field strains while maintaining high analytical sensitivity.

Metatranscriptomic Sequencing: A Novel Tool for Discovery and Surveillance

Beyond targeted PCR, metatranscriptomic (RNA-seq) sequencing has emerged as a powerful, untargeted approach for the detection of RNA viruses. This method sequences all RNA transcripts in a given sample, allowing for the simultaneous detection of known and novel pathogens without a priori assumptions about their identity. Recent work evaluating this technique for bovine respiratory viruses has demonstrated that sequencing depth and reference genome choice are critical determinants of success [15]. For a low-abundance virus like BIV, achieving detection from nasal swabs or blood samples would likely require a sequencing depth of at least 20 million reads per sample to capture the sparse viral transcripts amidst a sea of host and commensal microbial RNA. Furthermore, the choice of reference genome is paramount; mapping against a divergent field strain, rather than the prototype R29 reference strain, can dramatically increase read recovery and genome coverage, as has been shown for Bovine Viral Diarrhea Virus (BVDV-1) [15]. This methodological insight is particularly relevant for BIV, given the known genetic divergence between North American isolates, for which the R29 strain is the prototype, and European or Asian field strains [5]. The adoption of metatranscriptomics in BIV diagnostics would not only confirm infection but also provide invaluable data on viral diversity, recombination events, and the emergence of novel quasispecies, thereby informing the design of future PCR primers and serological antigens.

Virus Isolation and Bioassay: Historical Cornerstones

While molecular and serological methods have largely supplanted them, virus isolation and bioassay played a foundational role in the initial characterization of BIV. The original isolation of the R29 strain from a dairy cow in Louisiana involved the co-cultivation of peripheral blood leukocytes with fetal bovine lung cells [5]. The virus was identified by the presence of syncytia, large multinucleated giant cells formed by cell-to-cell fusion driven by the viral envelope protein, and by the detection of reverse transcriptase activity in culture supernatants. This cell culture system, however, is notoriously finicky; BIV replicates slowly, produces low titers, and is often overgrown by adventitious agents. The use of bioassay, where whole blood or milk is inoculated into seronegative calves, remains the gold standard for proving infectivity. For instance, studies on the thermal inactivation of BIV in milk relied on bioassay in calves, followed by monitoring for seroconversion over several months [3]. The concordance between these historical methods and modern recombinant-protein Western blots was demonstrated to be high, with 100% agreement when using the p26 antigen [2]. This suggests that while impractical for routine use, the biological relevance of the bioassay remains the ultimate truth standard against which all other diagnostic methods should be validated.

Future Directions: Towards a Standardized Diagnostic Framework

The path forward for BIV diagnostics lies in the convergence of multiple technologies. First, there is an urgent need for a multicenter validation study comparing the recombinant p26/tTM Western blot against a panel of reference PCR assays, using a geographically diverse set of field samples. This would establish a "gold standard" for future test development. Second, the adaptation of the recombinant proteins to a high-throughput ELISA format, similar to the barcoded magnetic bead (BMB) technology used for simultaneous detection of Feline Leukemia Virus antigen and FIV antibody, could allow for the multiplexed screening of cattle for BIV, BLV, and BVDV in a single well [16, 17]. Such platforms are particularly attractive for commercial diagnostic laboratories, as they minimize sample volume requirements and reduce labor costs while maintaining high analytical sensitivity. The success of such an assay would hinge on the elimination of cross-reactivity, a challenge that the existing Western blot data suggests is achievable [2].

Finally, the integration of diagnostic data into centralized epidemiological databases, modeled after the Irish BVD eradication program [7], would transform BIV from a research curiosity into a manageable herd health concern. The systematic testing of bulk tank milk or pooled ear-notch samples using a future validated RT-qPCR assay could provide prevalence estimates, identify infected cohorts, and guide management interventions. Without such a standardized diagnostic framework, BIV will remain an underdiagnosed and underestimated contributor to the complex spectrum of bovine infectious disease.

Clinical Manifestations and Pathological Findings in BIV-Infected Cattle

Overview of the Clinical Spectrum in Bovine Immunodeficiency Virus Infection

Bovine immunodeficiency virus (BIV), a lentivirus within the Retroviridae family, establishes a persistent infection in cattle that is characterized by a protracted, often subclinical course, punctuated by progressive immunological deterioration and susceptibility to secondary pathogens. Unlike the fulminant, acutely cytopathic infections caused by viruses such as bovine viral diarrhea virus (BVDV) or bovine herpesvirus-1 (BoHV-1), BIV infection is insidious, mirroring in many respects the clinical trajectory observed in feline immunodeficiency virus (FIV) infection in cats and human immunodeficiency virus (HIV) infection in humans. The clinical manifestations and pathological findings in BIV-infected cattle are therefore not attributable to direct viral cytopathology alone but are instead a complex interplay of lentiviral-mediated immune dysregulation, secondary opportunistic infections, and multisystemic degenerative changes that may take months to years to become clinically apparent. A thorough appreciation of these manifestations is essential for differential diagnosis, herd-level surveillance, and the development of effective management strategies, particularly as BIV has been detected in cattle populations across multiple continents, including North America, Europe, and Asia [4, 5]. The economic implications of BIV infection are compounded by its tendency to exacerbate the pathogenicity of concurrent infections, such as bovine leukemia virus (BLV) and bovine foamy virus (BFV), which are frequently detected in association with BIV [4].

Immunological Dysfunction and the Lentiviral Pathogenesis

The fundamental pathological hallmark of BIV infection is a progressive, lentivirus-induced immunodeficiency. The virus exhibits a tropism for cells of the monocyte/macrophage lineage, and to a lesser extent, lymphocytes, leading to a state of chronic immune activation followed by eventual immune exhaustion. This is analogous to the pathogenesis observed in FIV, where infection leads to lymphopenia, dysregulation of cytokine networks, and a heightened susceptibility to a wide range of secondary infections [8, 12]. In BIV-infected cattle, the initial phase of infection is often clinically silent, with no overt signs of disease during the first weeks to months post-exposure. However, during this period, the virus is actively replicating in lymphoid tissues, establishing a reservoir that is largely refractory to immune clearance. The ensuing chronic immune activation is reflected in hematological and biochemical alterations. Infected animals frequently exhibit hyperglobulinemia, particularly a polyclonal gammopathy, which is a direct consequence of persistent B-cell stimulation by viral antigens and dysregulated T-helper cell function [5, 8]. This hyperglobulinemia is often accompanied by a concurrent hypoalbuminemia, resulting in a decreased albumin-to-globulin ratio, a finding that is a sensitive, albeit non-specific, indicator of chronic inflammatory or infectious processes [8, 12]. While comprehensive longitudinal hematological studies in BIV-infected cattle under field conditions remain limited, studies in other lentiviral infections, such as FIV, have demonstrated that infected individuals frequently present with anemia (often non-regenerative), neutropenia, and thrombocytopenia [12, 21]. These cytopenias are likely multifactorial in origin, stemming from immune-mediated destruction, bone marrow suppression by viral infection or secondary cytokines, and the myelosuppressive effects of concurrent infections. The erythrocyte sedimentation rate (ESR), a marker of inflammation that is gaining traction in veterinary medicine, is also elevated in lentiviral infections, correlating with the degree of hyperglobulinemia and systemic inflammation [6].

Lymphoreticular System: Lymphadenopathy and Lymphoid Depletion

The lymphoreticular system bears the brunt of BIV's pathological impact. The most consistently reported macroscopic finding in BIV-infected cattle is generalized lymphadenopathy. This is typically a moderate, symmetrical enlargement of peripheral and visceral lymph nodes, which on cut section may appear fleshy and edematous. Histologically, this lymphadenopathy in the early to middle stages of infection is characterized by marked follicular hyperplasia, with prominent germinal centers and an expansion of the paracortical T-cell zones. This represents the host's futile attempt to control viral replication. However, as the infection progresses into the later, more immunodeficient stages, a striking transition occurs: the lymphoid follicles undergo progressive involution and eventual depletion. Germinal centers become atrophic or entirely disappear, and the paracortex becomes hypocellular, replaced by a stroma of hyalinized connective tissue and plasma cells. This pattern of lymphoid depletion is the histopathological correlate of the terminal immunosuppressive phase of the disease, rendering the animal exquisitely vulnerable to opportunistic invaders [5]. The spleen may also be affected, showing a similar pattern of follicular hyperplasia followed by atrophy of the white pulp. This dual pathology of initial hyperplasia and subsequent depletion is a defining characteristic of lentiviral infections, reflecting the eventual collapse of the immune system's regulatory architecture.

Respiratory Tract and the Syndrome of Secondary Pneumonia

Given the BIV-induced immunocompromised state, the respiratory tract is a primary target for secondary infections. The classic clinical presentation of a BIV-infected animal in the later stages of disease is a chronic, non-responsive pneumonia that fails to resolve with standard antimicrobial therapy. Affected cattle present with a persistent cough, nasal discharge (which may be serous to mucopurulent), tachypnea, and a decreased exercise tolerance. On auscultation, crackles and wheezes may be heard over affected lung fields. The pathological basis of this is a secondary bacterial or viral bronchopneumonia, often involving organisms that are normally cleared by a competent immune system. Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni are common bacterial isolates, but the infection may also be complicated by viruses such as bovine respiratory syncytial virus (BRSV), parainfluenza-3 virus (PI-3), or bovine herpesvirus-1 (BoHV-1) [19, 20]. At necropsy, the lungs show cranioventral consolidation, with affected lobules appearing firm, dark red to gray, and often containing foci of necrosis or abscessation. Histologically, there is a suppurative bronchopneumonia with evidence of a poor leukocyte response; the alveoli are filled with neutrophils, macrophages, and fibrin, but the inflammatory infiltrate may be less robust than in an immunocompetent animal, reflecting the underlying leukocyte dysfunction. The presence of a concurrent BIV infection should always be considered in cases of "atypical" or recurrent bovine respiratory disease complex (BRDC) that do not respond to treatment as expected.

Mammary Gland and Milk Production Alterations

The impact of BIV infection on the mammary gland is of significant economic concern, as it directly affects milk yield and quality. Clinical mastitis, often of a chronic or recurrent nature, is a prominent feature in BIV-seropositive dairy cows. The immunodeficiency predisposes the mammary gland to invasion by environmental pathogens, including coliforms, streptococci, and staphylococci, which are normally contained by the local and systemic immune defenses. The resultant mastitis is frequently subclinical or mild, presenting as an elevated somatic cell count (SCC) in the bulk tank milk without overt signs of clinical inflammation. However, it can also manifest as acute, clinical mastitis with visibly abnormal milk, swelling, and pyrexia. The pathological changes in the mammary gland include interstitial and intra-alveolar infiltration of mononuclear cells, fibrosis, and atrophy of the secretory epithelium [1, 19]. Chronic inflammation leads to a progressive loss of functional mammary parenchyma, which is a direct cause of the decreased milk production observed in BIV-infected herds [5]. Furthermore, the virus itself can be shed into milk, a finding of critical importance for both horizontal transmission within the herd and potential zoonotic concerns, though the latter remains unproven [3, 19]. The presence of BIV RNA in milk from cows with clinical respiratory signs has been documented, underscoring the systemic nature of the infection and the potential for milk to serve as a vector for transmission [19]. This is a crucial differential consideration in herds with unexplained, persistent elevations in bulk tank SCC or declining milk production trends.

Reproductive System and Fertility Impairments

Reproductive performance is severely compromised in BIV-infected cattle. The chronic disease state, characterized by systemic inflammation and immune dysregulation, has profound effects on fertility. Infected cows exhibit reduced conception rates, increased intervals from calving to conception, and a higher incidence of early embryonic death. The pathological mechanisms are multifactorial and include direct effects of chronic inflammation on the ovarian and uterine environment, as well as an increased susceptibility to opportunistic reproductive tract infections. Endometritis, caused by bacteria such as Trueperella pyogenes and Escherichia coli, is a common finding in BIV-infected cows, contributing to implantation failure and early pregnancy loss. The pathological changes within the uterus include a chronic, suppurative to lymphoplasmacytic endometritis, with fibrosis of the endometrial stroma and atrophy of the endometrial glands [1, 5]. In pregnant animals, BIV infection increases the risk of abortion and stillbirth. The virus itself can cross the placenta, leading to the birth of infected calves that may be weak, have a low birth weight, and are more susceptible to neonatal infections and mortality [1, 5]. This vertical transmission establishes a cycle of infection within the herd, with persistently infected animals serving as a continuous source of the virus. The economic impact of these reproductive losses, extended calving intervals, increased culling rates for infertility, and reduced calf crops, is a major driver of the decreased profitability associated with BIV-positive herds [1, 5].

Dermatological, Mucosal, and Other Systemic Manifestations

A spectrum of dermatological and mucosal lesions is also observed in BIV-infected cattle, reflecting the systemic nature of the immunodeficiency and the related immune complex deposition. Chronic, non-healing skin lesions, often presenting as exudative dermatitis or pyoderma, can occur. These are frequently complicated by secondary bacterial or fungal infections. Stomatitis and gingivitis, analogous to the severe oral disease seen in FIV-infected cats [12], are less commonly reported in cattle but can occur, particularly in animals with advanced immunodeficiency. Ocular lesions, including chronic conjunctivitis and keratitis, may also be present. Beyond these external manifestations, BIV-infected animals may exhibit a general decline in body condition, characterized by progressive weight loss and muscle wasting (cachexia), despite adequate feed intake. This is a hallmark of the chronic inflammatory state (the "wasting syndrome") driven by pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukins. Neurological signs, while not as prominent as in some other lentiviral infections (e.g., caprine arthritis-encephalitis virus), have been described and may include hindlimb paresis, ataxia, and behavioral changes, likely due to a combination of direct viral effects on the central nervous system and secondary inflammatory processes [5]. Concurrently, there is a well-documented increase in the incidence of intercurrent disease, including chronic diarrhea, and a higher case fatality rate for treatable conditions like bovine viral diarrhea (BVD) or enzootic bovine leukosis (EBL), as the compromised immune system is unable to mount an effective response [5, 9-11, 13]. This phenomenon of disease potentiation is a critical feature of BIV infection, transforming naturally self-limiting or manageable infections into severe, life-threatening events.

Pathological Findings: A Summary at the Tissue Level

At necropsy, the constellation of pathological findings in a BIV-infected animal is a reflection of the chronic immunosuppression and its sequelae. Grossly, aside from the generalized lymphadenopathy (often with later lymphoid atrophy) and splenomegaly followed by atrophy, the most common findings are related to secondary infections. These include cranioventral consolidation of the lungs (bronchopneumonia), suppurative to necrotic mastitis, and evidence of chronic endometritis. The carcass may be emaciated, and there may be evidence of systemic amyloidosis in chronic cases, secondary to the prolonged hyperglobulinemia. Histologically, the hallmark is the depletion of lymphoid tissues, with a lack of organized lymphoid follicles in the lymph nodes, spleen, and gut-associated lymphoid tissue (GALT). The bone marrow may show evidence of hypoplasia, particularly of the myeloid and erythroid lines. In the organs affected by secondary infections, the inflammatory response is often qualitatively and quantitatively altered, with a predominance of mononuclear cells and a relative paucity of neutrophils, even in the face of a bacterial infection. The presence of multinucleated giant cells (syncytia) is a characteristic, though not pathognomonic, finding in lentiviral infections and can be observed in lymph nodes and other tissues where viral replication is high. The pathological picture is therefore one of a "failing" immune system, where the host's tissue responses are inadequate to control pathogens, leading to a chronic, progressive, and ultimately fatal course of disease.

Transmission Routes and Risk Factors for Bovine Immunodeficiency Virus

The elucidation of transmission pathways for Bovine Immunodeficiency Virus (BIV) remains one of the most complex and critically understudied areas in veterinary retrovirology. Unlike its well-characterized counterparts in other species, such as the predominantly horizontal transmission of Feline Immunodeficiency Virus (FIV) via bite wounds [8, 12] or the multifaceted spread of Bovine Leukemia Virus (BLV) through iatrogenic and vector-mediated routes [1, 10], BIV presents a transmission ecology that is still being defined. The virus, a lentivirus within the Retroviridae family, establishes a persistent, life-long infection in cattle, yet the precise mechanisms by which it perpetuates within and between herds have only begun to be systematically investigated over the past two decades [4, 5]. Understanding these routes is not merely an academic exercise; it is foundational to developing evidence-based biosecurity protocols, risk assessment models, and potential eradication strategies for a pathogen that may be contributing to subclinical immunosuppression and production losses across global cattle populations.

Vertical Transmission: The Colostral and In Utero Conundrum

Vertical transmission, the passage of virus from dam to offspring, represents a critical pathway for the maintenance of BIV within a herd across generations. The evidence for this route is compelling but nuanced, centering on two primary mechanisms: in utero infection and lactogenic transmission via colostrum and milk.

Lactogenic Transmission and the Pasteurization Question: The presence of BIV in milk has been documented, raising significant questions about the risk posed to calves consuming unpasteurized milk or colostrum. Early bioassay studies directly addressed this concern by investigating whether BIV in milk could be inactivated by standard pasteurization protocols [3]. The findings from this foundational work indicated that pasteurization effectively inactivates BIV, rendering milk safe for consumption [3]. This is a critical biosecurity measure, analogous to the role pasteurization plays in controlling Mycobacterium bovis transmission in bovine tuberculosis [22, 24] and other milk-borne pathogens. However, the risk remains substantial on farms where raw milk feeding is practiced, a common management strategy for providing passive immunity to neonates. The consumption of raw colostrum from a BIV-seropositive dam represents a high-risk event, as the virus can directly access the neonatal gut-associated lymphoid tissue, a highly permissive environment for lentiviral entry and establishment.

In Utero and Periparturient Transmission: The potential for true in utero transmission, infection of the fetus during gestation, is more difficult to ascertain but is suggested by epidemiological patterns. The detection of BIV proviral DNA in fetal tissues or in calves prior to colostrum ingestion would provide definitive evidence, yet such studies are scarce. The biological plausibility is high, given that other ruminant lentiviruses, such as Maedi-Visna virus in sheep, can cross the placental barrier. Furthermore, the periparturient period presents another window of vulnerability. Calves can be exposed to virus present in maternal blood or vaginal secretions during parturition. The risk factors that modulate vertical transmission efficiency likely include maternal proviral load, the stage of maternal infection (with higher risk during the acute phase of viremia), and the presence of concurrent infections that may compromise the placental barrier. The persistence of BIV in herds, even in the absence of overt clinical disease, suggests that vertical transmission, particularly through the lactogenic route, is a steady, low-level mechanism for viral perpetuation [5].

Horizontal Transmission: Iatrogenic, Direct Contact, and the Enigma of Vector-Borne Spread

Horizontal transmission, the spread of virus between unrelated animals within a cohort, is likely the dominant driver of BIV prevalence in endemic herds. The routes involved are diverse, ranging from well-established iatrogenic mechanisms to more controversial vector-borne possibilities.

Iatrogenic Transmission: The Needle as a Vector: The most significant and well-documented risk factor for the horizontal spread of BIV is iatrogenic transmission, primarily through the reuse of contaminated needles and surgical equipment. This route is a well-recognized driver for other bovine retroviruses, most notably BLV, where the use of individual needles during veterinary procedures is the single most important protective factor against infection [10]. The parallels for BIV are striking. The virus is cell-associated, meaning it resides within infected lymphocytes and monocytes in the blood. Any procedure that transfers even microliters of blood from an infected to a susceptible animal, be it vaccination, antibiotic administration, blood collection, or tattooing, can efficiently transmit the virus. The risk is amplified in modern intensive dairy operations where large numbers of animals are processed rapidly. Dehorning, castration, and the use of multi-dose syringes without changing needles between animals are high-risk practices. The implementation of strict biosecurity protocols mandating single-use needles and rigorous sterilization of surgical instruments is therefore paramount, mirroring the successful strategies employed in BLV control programs [10, 11].

Direct Contact Transmission: Saliva, Blood, and Mucosal Exposure: The role of direct contact in BIV transmission is less clear than for FIV, where aggressive biting is the primary route [8, 12]. Cattle are not typically aggressive biters, but other forms of contact-mediated transfer are plausible. The virus can be present in saliva, and behaviors such as mutual grooming, sharing of feed bunks, and the use of common water troughs could facilitate oral or mucosal exposure. The risk is likely correlated with the degree of viremia and the presence of oral lesions or abrasions that could serve as portals of entry. Furthermore, the common practice of nose-to-nose contact between animals across fence lines represents a potential, albeit low-efficiency, route. The risk factors for direct contact transmission are therefore management-dependent; high stocking densities, poor ventilation, and mixing of animals from different sources (e.g., at sales yards or during herd expansion) increase the probability of effective contact and subsequent transmission.

Vector-Mediated Transmission: The Role of Hematophagous Arthropods: This remains the most controversial and actively researched area of BIV transmission. The question of whether blood-feeding insects and ticks can act as mechanical or biological vectors for BIV is of immense epidemiological importance, particularly in tropical and subtropical regions where arthropod burdens are high. Extrapolating from the extensive literature on BLV, the potential for vector-borne spread is significant. A comprehensive systematic analysis of the role of blood-sucking insects in BLV transmission has highlighted the importance of gadflies (Tabanidae family) and the stable fly (Stomoxys calcitrans) as mechanical vectors [1]. These insects are notorious for interrupted feeding behavior; they will begin feeding on an infected animal, be disturbed, and immediately complete their blood meal on a nearby susceptible host, effectively acting as a "flying needle."

The biological plausibility for BIV is supported by the fact that the virus is present in the peripheral blood of infected cattle. For mechanical transmission to occur, the virus must survive on the mouthparts of the insect for a sufficient duration to be transferred to the next host. While BIV is an enveloped virus and thus relatively fragile outside the host, the short time interval between interrupted feeds (often seconds to minutes) makes mechanical transmission by large tabanid flies highly feasible. The risk factors associated with this route are environmental and seasonal. Herds located near wooded areas, wetlands, or regions with high populations of biting flies are at elevated risk. The peak transmission season for BLV correlates with peak fly activity, and a similar pattern is hypothesized for BIV [1]. The role of ixodid ticks (hard ticks) is also under investigation. Ticks are capable of transstadial transmission (passing the virus from one life stage to the next), which could theoretically allow them to act as more than just mechanical vectors, potentially serving as a reservoir or amplifying host [1]. However, definitive evidence for biological replication of BIV within tick tissues is lacking. The presence of BIV genetic material in ticks collected from infected herds would be a crucial piece of evidence, but such studies remain to be conducted. The vector-borne hypothesis, while not definitively proven, is supported by the spatial clustering of BIV infections and the difficulty of explaining all transmission events through iatrogenic or direct contact routes alone.

Risk Factors: A Multifactorial Framework for Infection

The risk of BIV infection in an individual animal or herd is not determined by a single factor but by a complex interplay of management practices, host factors, and environmental conditions.

Management and Iatrogenic Risk Factors: As discussed, the reuse of needles and contaminated equipment is the paramount modifiable risk factor. Herd size is also a significant predictor; larger herds, particularly intensive dairy operations, have higher contact rates, greater turnover of animals, and more frequent veterinary interventions, all of which amplify transmission opportunities. The practice of purchasing replacement heifers from external sources without quarantine and testing introduces a constant risk of importing BIV-positive animals into a naive herd. This is analogous to the risks seen with Bovine Viral Diarrhea Virus (BVDV), where the introduction of persistently infected (PI) animals is the primary driver of outbreaks [7, 13]. For BIV, which lacks a clear PI state, the introduction of latently infected but seropositive animals is the analogous threat.

Host-Related Risk Factors: Age is a consistent risk factor for BIV, with seroprevalence typically increasing with age. This reflects the cumulative probability of exposure over an animal's lifetime, a pattern seen in many persistent viral infections. The presence of concurrent infections is a critical, yet poorly understood, risk factor. BIV is an immunosuppressive lentivirus, and co-infection with other pathogens, such as BLV, BVDV, or Mycobacterium avium subspecies paratuberculosis, may create a synergistic effect. Immunosuppression from BIV could increase susceptibility to secondary infections, while the immune activation caused by other pathogens could upregulate BIV replication, increasing proviral load and transmissibility. This associative nature of infection with leukemia, immunodeficiency, and spumavirus pathogens has been documented in Ukrainian cattle populations, suggesting that BIV may be part of a larger, complex infectious disease ecology [4].

Environmental and Vector-Related Risk Factors: Geographic location and climate are emerging as important risk factors, particularly if vector-borne transmission is confirmed. Herds in regions with warm, humid climates and prolonged fly seasons are theoretically at higher risk. The spatial analysis of other vector-borne diseases in cattle, such as Bluetongue virus (BTV) and Rift Valley fever virus (RVFV), demonstrates how environmental variables like rainfall, temperature, and vegetation indices can predict disease distribution [23, 24]. A similar geospatial approach, integrating data on vector abundance, climate variables, and BIV seroprevalence, would be invaluable for identifying high-risk zones and targeting control measures. The World Organisation for Animal Health (WOAH) recognizes the economic impact of retroviral diseases, and understanding these environmental drivers is essential for aligning BIV surveillance with existing frameworks for other vector-borne and blood-borne pathogens.

Immune Response and Host-Virus Interactions in Bovine Immunodeficiency Virus Infection

The immune response to Bovine Immunodeficiency Virus (BIV) represents a complex, dynamic interplay between a persistent lentiviral pathogen and the bovine host’s multifaceted defense systems. Understanding these interactions is critical not only for elucidating the pathogenesis of BIV-associated disease but also for informing the development of effective diagnostic tools, vaccines, and management strategies. As a lentivirus, BIV shares fundamental biological properties with other members of the Retroviridae family, including Human Immunodeficiency Virus (HIV) and Feline Immunodeficiency Virus (FIV), establishing a chronic infection characterized by progressive immune dysfunction, lifelong viral persistence, and a protracted clinical course [5]. The host-virus equilibrium is established early in infection, shaped by the virus’s ability to subvert innate defenses, evade adaptive immunity, and exploit the very cells responsible for immune surveillance.

Innate Immune Recognition and Early Antiviral Responses

The initial encounter between BIV and the bovine host triggers a cascade of innate immune mechanisms designed to limit viral replication and dissemination. Upon entry, typically through parenteral routes such as blood-feeding arthropods (e.g., tabanid flies or ixodid ticks) or iatrogenic procedures, BIV encounters sentinel cells of the innate immune system, including macrophages, dendritic cells, and natural killer (NK) cells [1, 5]. Pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), and cytosolic DNA sensors, are poised to detect viral pathogen-associated molecular patterns (PAMPs). For BIV, a single-stranded RNA virus with a reverse transcription step, the primary PAMPs include viral genomic RNA, double-stranded RNA intermediates generated during replication, and potentially viral DNA products. Engagement of these PRRs initiates signaling cascades that culminate in the production of type I interferons (IFN-α/β), pro-inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α), and chemokines.

The induction of an interferon-stimulated gene (ISG) program is a cornerstone of the antiviral state. ISGs such as MX proteins, 2',5'-oligoadenylate synthetase (OAS), and tetherin (BST-2) act to restrict viral replication at multiple stages, from inhibiting viral entry and uncoating to blocking budding and release. However, lentiviruses, including BIV, have evolved sophisticated countermeasures to antagonize these innate defenses. The BIV accessory proteins, analogous to HIV’s Vif, Vpu, and Nef, are hypothesized to play critical roles in neutralizing host restriction factors. For instance, the BIV Vif-like protein is predicted to target the bovine APOBEC3 family of cytidine deaminases, which would otherwise hypermutate the viral genome during reverse transcription, rendering the provirus non-functional. The efficiency of this antagonism is a key determinant of early viral replication kinetics and the establishment of a stable proviral reservoir. The initial inflammatory milieu, while intended to control infection, can paradoxically facilitate viral spread by recruiting activated CD4+ T lymphocytes and monocytes, the primary target cells for BIV, to sites of infection, thereby providing a fresh supply of susceptible cells.

Cellular Targets and the Establishment of Viral Reservoirs

BIV exhibits a tropism for cells of the monocyte/macrophage lineage and, to a lesser extent, lymphocytes. This cellular tropism is dictated by the interaction between the viral envelope glycoprotein (Env) and the host cell receptor, which for BIV is believed to be a molecule distinct from the CD4 receptor used by HIV, potentially involving a chemokine receptor or an alternative entry mediator. Once inside the cell, the viral RNA genome is reverse transcribed into double-stranded DNA, which is then integrated into the host cell genome as a provirus. This integration event is a defining feature of retroviral infection, ensuring lifelong persistence. Macrophages are particularly insidious reservoirs for BIV. As long-lived, terminally differentiated cells that are resistant to the cytopathic effects of viral replication, they can harbor and produce virus for extended periods. Furthermore, tissue-resident macrophages, such as alveolar macrophages in the lung and Kupffer cells in the liver, can serve as sanctuaries where the virus is shielded from immune surveillance and antiviral drugs.

The establishment of a latent proviral reservoir in resting CD4+ T cells is another hallmark of lentiviral infection. While BIV can productively infect activated T cells, a small fraction of infected cells reverts to a quiescent memory state, carrying an integrated but transcriptionally silent provirus. These latently infected cells are invisible to the immune system and are not affected by antiretroviral therapy, representing a major barrier to viral eradication. The mechanisms governing latency in BIV are likely similar to those described for HIV, involving epigenetic silencing of the viral long terminal repeat (LTR) promoter, chromatin remodeling, and a lack of key host transcription factors (e.g., NF-κB, NFAT) in resting cells. Reactivation from latency can be triggered by cellular activation signals, such as those encountered during concurrent infections or inflammatory responses, leading to bursts of viral replication and replenishment of the active viral pool.

Humoral Immune Response and Antibody-Mediated Control

The humoral immune response to BIV is characterized by the production of antibodies against a variety of viral structural and regulatory proteins. The major capsid protein p26 and the transmembrane envelope protein (TM) are highly immunogenic and serve as the primary targets for serological diagnosis [2]. The development of a recombinant protein-based Western blot assay using baculovirus-expressed p26 and a truncated TM (tTM) protein has proven to be a highly specific and sensitive method for detecting anti-BIV antibodies in bovine serum, demonstrating 100% concordance with a reference Western blot using whole virions when the p26 antigen was employed [2]. This assay is critical for distinguishing BIV infection from other bovine retroviruses, such as Bovine Leukemia Virus (BLV) and Bovine Syncytial Virus, as no cross-reactivity was observed [2].

Despite the robust antibody response, the humoral arm of the immune system is largely ineffective at clearing established BIV infection. The virus employs several immune evasion strategies to circumvent neutralizing antibodies. The BIV envelope glycoprotein is heavily glycosylated, forming a "glycan shield" that masks conserved neutralizing epitopes from antibody recognition. Furthermore, the envelope protein exhibits a high degree of sequence variability, particularly in the surface unit (SU) region, allowing the virus to escape from antibody pressure through the selection of neutralization-resistant variants. Antibodies may also facilitate infection through antibody-dependent enhancement (ADE), a phenomenon observed in other lentiviral infections where suboptimal or non-neutralizing antibodies enhance viral entry into Fc receptor-bearing cells, such as macrophages. The presence of hypergammaglobulinemia, a polyclonal activation of B cells, is a common finding in chronic lentiviral infections and reflects the ongoing immune dysregulation [6, 8]. This non-specific B cell activation, while contributing to total antibody levels, does not translate into effective antiviral immunity and may even contribute to autoimmune phenomena.

Cell-Mediated Immunity and T Cell Dysfunction

Given the limitations of the humoral response, cell-mediated immunity, particularly the activity of cytotoxic T lymphocytes (CTLs) and CD4+ T helper cells, is considered the primary driver of viral control. BIV-specific CTLs recognize viral peptides presented on the surface of infected cells by major histocompatibility complex (MHC) class I molecules. These CTLs can kill productively infected cells before they release new virions, thereby reducing the viral load. However, BIV, like HIV, has evolved mechanisms to evade CTL responses. The virus can downregulate MHC class I expression on the surface of infected cells, making them less visible to CTLs. This is often mediated by the viral Nef protein, which redirects MHC-I molecules to the lysosome for degradation. Additionally, the high mutation rate of the virus allows for the emergence of CTL escape variants that harbor mutations in key epitopes, preventing T cell receptor recognition.

CD4+ T cells are central to orchestrating both humoral and cellular immune responses. They provide essential help for B cell differentiation and antibody production and are critical for the generation and maintenance of memory CTL responses. Paradoxically, these very cells are the preferred targets for BIV infection. The progressive depletion of CD4+ T cells, a hallmark of HIV/AIDS, is also observed in BIV infection, albeit often with a more protracted time course. The mechanisms of CD4+ T cell loss are multifactorial and include direct viral cytolysis, activation-induced cell death (AICD) due to chronic immune activation, and bystander killing of uninfected cells by viral proteins or inflammatory mediators. The resulting immunodeficiency, characterized by a declining CD4+ T cell count and a skewed CD4+/CD8+ T cell ratio, renders the host susceptible to opportunistic infections and secondary diseases. This state of acquired immunodeficiency is analogous to that seen in FIV-infected cats, where it predisposes to a range of secondary infections, neoplasia (notably lymphoma), and neurological disease [8, 12, 14, 26]. The chronic immune activation, driven by persistent viral replication and microbial translocation from a damaged gut mucosa, is a key driver of immune exhaustion and senescence, leading to a state of functional unresponsiveness in both CD4+ and CD8+ T cells.

Immune Dysregulation and Clinical Consequences

The culmination of these host-virus interactions is a state of profound immune dysregulation. The chronic inflammatory state, marked by elevated levels of pro-inflammatory cytokines and acute-phase proteins, contributes to the systemic clinical manifestations of BIV infection. Hematological abnormalities, including anemia, thrombocytopenia, and leukopenia, are frequently observed and are indicative of bone marrow suppression or peripheral destruction of blood cells [8, 12]. The erythrocyte sedimentation rate (ESR), a non-specific marker of inflammation, is elevated in lentiviral infections and correlates with disease severity, as demonstrated in FIV-infected cats [6]. Similarly, alterations in serum protein profiles, such as hypoalbuminemia and hyperglobulinemia, reflect the ongoing inflammatory and B cell-activating processes [8, 12].

The virus’s impact on the host’s ability to mount effective immune responses has significant implications for herd health. BIV-infected cattle may be more susceptible to concurrent infections with other pathogens, such as Mycobacterium bovis (the causative agent of bovine tuberculosis), Rhodococcus equi, or respiratory viruses like Bovine Viral Diarrhea Virus (BVDV) and Bovine Herpesvirus-1 (BoHV-1) [7, 19, 20, 22, 25]. The immunosuppressive effects of BIV can also exacerbate the clinical course of other retroviral infections, such as BLV, leading to more rapid progression to lymphosarcoma [4, 10, 11]. Furthermore, the presence of BIV may complicate the interpretation of diagnostic tests for other diseases, as the immune dysregulation can lead to false-positive or false-negative results. The economic impact of BIV on the dairy and beef industries is likely underestimated, as subclinical infections may contribute to reduced milk production, decreased fertility, increased rates of mastitis, and a higher incidence of other production-limiting diseases [5]. The detection of BIV genetic material in cattle in Ukraine, often in association with BLV and bovine foamy virus, underscores the complex, multi-pathogen nature of retroviral infections in livestock and the need for comprehensive diagnostic and control strategies [4].

Prevention, Control Strategies, and Biosecurity Measures for Bovine Immunodeficiency Virus

The development and implementation of robust prevention, control, and biosecurity strategies for Bovine Immunodeficiency Virus (BIV) are hampered by a constellation of factors that distinguish it from other, more well-characterized bovine retroviruses such as Bovine Leukemia Virus (BLV). Unlike BLV, which has been the target of successful eradication programs in numerous countries [11], BIV infection is typically subclinical, and its direct economic impact on herd productivity remains a subject of ongoing investigation rather than a settled fact. This ambiguity has historically relegated BIV to the status of a "minor" or "insufficiently studied" viral infection [4], resulting in a lack of dedicated, large-scale control initiatives. Consequently, the prevention and control framework for BIV must be constructed from a synthesis of general retrovirus biosecurity principles, lessons learned from BLV and Bovine Viral Diarrhea Virus (BVDV) eradication programs, and the specific, albeit limited, biological data available for BIV itself. The overarching goal is not necessarily eradication, but the reduction of viral prevalence and the mitigation of any potential immunosuppressive effects that could predispose cattle to secondary infections or reduce vaccine efficacy.

Understanding Transmission Pathways as a Foundation for Control

A rational biosecurity program must be predicated on a precise understanding of how the pathogen is transmitted. For BIV, the transmission routes are less definitively characterized than for BLV, but the available evidence points to a multifaceted epidemiology. Horizontal transmission via iatrogenic means is considered a primary concern. The reuse of contaminated needles, surgical instruments (e.g., dehorners, tattoo equipment), and rectal sleeves for palpation are well-established vectors for blood-borne pathogens like BLV [10]. Given that BIV is a cell-associated virus present in peripheral blood leukocytes, these same iatrogenic pathways are highly plausible and likely represent a significant, preventable route of transmission within and between herds. The use of individual needles for every animal during vaccinations, treatments, and blood collection is therefore a non-negotiable, foundational biosecurity measure, a principle strongly validated by its protective effect against BLV [10].

The role of colostrum and milk in BIV transmission is another critical consideration. Early research demonstrated that BIV can be present in milk, but crucially, standard pasteurization protocols were shown to effectively inactivate the virus [3]. This finding has profound implications for control. It provides a clear and effective mitigation strategy for preventing lactogenic transmission to calves. Feeding calves pasteurized waste milk or a milk replacer, rather than raw bulk tank milk, should be a standard recommendation for BIV control, particularly in herds with known or suspected seropositive animals. This measure also serves as a critical control point for a host of other pathogens, including Mycobacterium bovis (the causative agent of bovine tuberculosis) [24] and BVDV, thereby offering a broad-spectrum biosecurity benefit.

Vector-borne transmission remains a contentious and unresolved issue for BIV, mirroring the debate surrounding BLV. A systematic analysis of the literature on BLV has highlighted the potential role of blood-sucking insects, particularly tabanid flies (gadflies) and the stable fly (Stomoxys calcitrans), as well as ixodid ticks, in mechanical transmission [1]. These insects can cause interrupted feeding, moving from an infected to a susceptible host while carrying a blood meal on their mouthparts. The same biological principle applies to BIV. While direct evidence for insect transmission of BIV is lacking, the high viral load in the blood of infected animals and the feeding behavior of these arthropods create a strong theoretical risk. Therefore, integrated pest management (IPM) strategies should be considered a secondary but valuable component of a comprehensive BIV control plan. This includes the strategic use of insecticides, ear tags, pour-ons, and environmental management to reduce fly breeding sites (e.g., manure management, proper disposal of soiled bedding). The risk is amplified during periods of high insect activity and when large numbers of infected animals are present [1].

Diagnostic Surveillance and Herd Management Strategies

The cornerstone of any effective control program is a reliable diagnostic test. For BIV, serological detection of antibodies remains the primary method. The development of a Western blot assay using recombinant BIV capsid (p26) and transmembrane envelope (tTM) proteins has provided a highly specific and sensitive tool for confirming infection [2]. This assay is critical for differentiating BIV from other bovine retroviruses like BLV and bovine syncytial virus, which can cause serological cross-reactivity [2]. However, the widespread adoption of BIV testing is not yet a reality. The virus is not included in routine diagnostic panels, and its detection is largely confined to research settings [4]. For a control strategy to be implemented, a shift towards more accessible, high-throughput testing, such as ELISA-based methods, would be necessary. The development of such assays for other retroviruses, like the rapid indirect ELISA for FIV [17] or barcoded magnetic bead-based immunoassays for FeLV/FIV [16], provides a technological roadmap that could be adapted for BIV.

In the absence of a vaccine or a test-and-slaughter policy, the primary management strategy for BIV is risk-based segregation and biosecurity. Drawing from the successful Irish BVDV eradication program, which relied on identifying and removing persistently infected (PI) animals [7], a similar, though less aggressive, approach could be applied to BIV. The first step is to establish the infection status of the herd through targeted serological surveillance. This could involve testing a statistically significant sample of animals, with a focus on older animals who are more likely to have been exposed. Once the herd status is known, management practices can be stratified. For example, in a herd with high BIV seroprevalence, the focus should be on preventing the introduction of new infections and reducing the viral load within the herd. This can be achieved by:

1. Quarantine and Testing: All new introductions to the herd should be sourced from BIV-negative herds or, failing that, quarantined and tested for BIV antibodies before being allowed to commingle with the main herd. A negative test at entry does not guarantee freedom from infection due to the window period, so a second test 30-60 days later is advisable.
2. Cohort Management: Calves born to seropositive dams should be considered at high risk. They should be fed pasteurized colostrum and milk [3] and managed in a separate cohort to minimize the risk of horizontal transmission to calves from negative dams. This is analogous to the management of BVDV PI calves, where separation is critical to breaking the cycle of transmission [7].
3. Needle and Instrument Hygiene: As previously emphasized, strict adherence to single-use needle protocols is paramount. This single intervention, proven to be a major protective factor against BLV [10], is likely the most cost-effective and impactful biosecurity measure for BIV.

The Role of Disinfection and Environmental Control

BIV is an enveloped virus, rendering it inherently susceptible to a wide range of disinfectants. This is a significant advantage for biosecurity. Enveloped viruses are generally inactivated by lipid solvents, detergents, and common disinfectants. While specific efficacy data against BIV is scarce, the principles applied to other enveloped veterinary pathogens, such as African swine fever virus (ASFV), are directly relevant. Studies on ASFV have demonstrated that many commercially available disinfectants, including those based on aldehydes, quaternary ammonium compounds, and oxidizing agents, exhibit potent virucidal activity [27]. It is critical, however, to ensure that the chosen disinfectant is used at the correct concentration and contact time, and that organic matter (manure, blood, milk) is removed prior to application, as organic load can significantly reduce disinfectant efficacy [27].

Environmental decontamination should focus on high-contact surfaces and equipment. This includes:

• Calf housing and maternity pens: These areas are high-risk due to the presence of bodily fluids (blood, placenta, colostrum). They should be cleaned and disinfected between uses.
• Veterinary and handling equipment: Syringes, needles, nose tongs, and rectal sleeves should be considered single-use or thoroughly disinfected between animals.
• Transport vehicles: Trucks and trailers used to move cattle should be cleaned and disinfected between loads to prevent mechanical transmission.

Integrating BIV Control into a Comprehensive Herd Health Program

Ultimately, the most effective strategy for BIV is not to manage it in isolation, but to integrate its control into a comprehensive, multi-pathogen biosecurity and herd health program. The economic justification for BIV-specific measures is strengthened when they are bundled with controls for pathogens with a clearer economic impact, such as BLV, BVDV, and bovine tuberculosis (bTB) [22, 24]. For instance, the same single-use needle policy that prevents BLV transmission also prevents BIV transmission. The same pasteurization protocol that inactivates M. bovis [24] also inactivates BIV [3]. The same quarantine and testing protocols for BVDV can be adapted to include BIV.

The detection of BIV genetic material in cattle in Ukraine, often in association with BLV and bovine foamy virus [4], underscores the reality of co-infections. The potential for BIV-induced immunosuppression to exacerbate the pathology of other infections is a key concern. While the clinical significance of BIV is debated, a precautionary principle should guide veterinary practice. By implementing robust biosecurity measures aimed at controlling known economically significant pathogens, the veterinary community is, by default, implementing the most effective known controls for BIV. Future research should focus on developing cost-effective, high-throughput diagnostic tools and conducting longitudinal field studies to definitively quantify the production impacts of BIV, both alone and in co-infection scenarios. Only with such data can the cost-benefit analysis of a dedicated BIV control program be accurately calculated, potentially elevating it from a "minor" infection [4] to a target of active, funded surveillance and management, following the successful models established for BLV in Italy [11] and BVDV in Ireland [7].

References

[1] Osipova N, Agarkova T, Dvoeglazov NG, Gendzhiev A, Gulyukin MI. The role of blood-sucking insects and ixodid ticks in the possible transmission of bovine leukemia virus. Siberian Herald of Agricultural Science. 2026. DOI: https://doi.org/10.26898/0370-8799-2026-4-10

[2] Abed Y, St‐Laurent G, Zhang H, Jacobs RM, Archambault D. Development of a Western Blot Assay for Detection of Bovine Immunodeficiency-Like Virus Using Capsid and Transmembrane Envelope Proteins Expressed from Recombinant Baculovirus. Clinical Diagnostic Laboratory Immunology. 1999. DOI: https://doi.org/10.1128/CDLI.6.2.168-172.1999

[3] Venables C, Lysons R, Horigan M, Stagg D, Dawson M. Bovine immunodeficiency-like virus. American Association of Bovine Practitioners Conference Proceedings. 1997. DOI: https://doi.org/10.21423/aabppro19975841

[4] Gorbatenko S, Kornieikova OB, Rudova NG, Dunaiev Y, Stegniy B, Kornieikov O. Insufficiently studied minor viral infections in livestock of Ukraine. Journal for veterinary medicine, biotechnology and biosafety. 2023. DOI: https://doi.org/10.36016/jvmbbs-2023-9-1-2-2

[5] Li Y. Power analysis for a mixed effects logistic regression model. . 2006. DOI: https://doi.org/10.31390/gradschool_dissertations.244

[6] Donato G, Caspanello T, Caprì A, Majo MD, Iannelli N, Rosace F, et al.. The erythrocyte sedimentation rate and other markers of inflammation in cats tested for Leishmania infantum and feline immunodeficiency virus antibodies. Parasites & Vectors. 2024. DOI: https://doi.org/10.1186/s13071-024-06396-1

[7] Graham D, More S, O'Sullivan P, Lane E, Barrett D, Lozano J, et al.. The Irish Programme to Eradicate Bovine Viral Diarrhoea Virus, Organization, Challenges, and Progress. Frontiers in Veterinary Science. 2021. DOI: https://doi.org/10.3389/fvets.2021.674557

[8] Carlton C, Norris J, Hall E, Ward M, Blank S, Gilmore S, et al.. Clinicopathological and Epidemiological Findings in Pet Cats Naturally Infected with Feline Immunodeficiency Virus (FIV) in Australia. Viruses. 2022. DOI: https://doi.org/10.3390/v14102177

[9] Bashenova E, Kirpichenko V, Nissanova R, Mamanova S, Dyusenov SM, Lesov B, et al.. DIAGNOSIS OF BOVINE VIRAL DIARRHEA: THE IMPORTANCE OF STANDARDIZING CONTROL SERA FOR INTERLABORATORY COMPARISONS. Ġylym ža̋ne bìlìm. 2025. DOI: https://doi.org/10.52578/2305-9397-2025-3-1-237-248

[10] Ortega D, anchez AD, on JT, Chaparro Y, es SC, errez MiFG. Seroprevalence and risk factors associated with bovine leukemia virus in Colombia. Journal of Veterinary Medicine and Animal Health. 2016. DOI: https://doi.org/10.5897/JVMAH2016.0457

[11] Righi C, Iscaro C, Petrini S, Lomolino R, Feliziani F. Enzootic Bovine Leukosis in Italy: Epidemiological Issues after Free Status Recognition and Measures Applied to Tackle the Last Persistent Clusters. Pathogens. 2021. DOI: https://doi.org/10.3390/pathogens10111475

[12] Kot Z, Ozcan U. Evaluation of PT, APTT, Fibrinogen, CBC-Derived Inflammation Indices (NLR, MLR, EOLR, PLR) and Clinical Findings in FIV-Infected Cats. Turkish Journal of Agriculture - Food Science and Technology. 2026. DOI: https://doi.org/10.24925/turjaf.v14i5.1305-1312.8600

[13] Afify A, Hassanien RT, Abdelmegeed HK, Abouelyazeed EA, Ali MH, Abdelwahed DA, et al.. First detection of emerging HoBi-like Pestivirus (BVD-3) among some persistently infected dairy cattle herds in Egypt. Tropical Animal Health and Production. 2022. DOI: https://doi.org/10.1007/s11250-022-03332-2

[14] Pérez E, Gonzalez O, Dolz G, Morales J, Barr B, Conrad P. First report of bovine neosporosis in dairy cattle in Costa Rica. The Veterinary Record. 1998. DOI: https://doi.org/10.1136/vr.142.19.520

[15] Brito B, Frost M, Webster J, To J, Kirkland PD. Quantifying the impact of sequencing depth and reference genome choice on metatranscriptomic detection of four bovine RNA viruses.. Research in Veterinary Science. 2026. DOI: https://doi.org/10.1016/j.rvsc.2026.106125

[16] Esty K, Elmer H, Nassar S, Ruggiero A, Singh S, Beall M, et al.. Evaluation of barcoded magnetic bead–based immunoassays for the simultaneous detection of feline leukemia virus antigen and antibody against feline immunodeficiency virus. Journal of Veterinary Diagnostic Investigation. 2022. DOI: https://doi.org/10.1177/10406387221129259

[17] Ferrero I, Poletti P, Giachino E, Filipe J, Dall'Ara P. A New Rapid Indirect ELISA Test for Serological Diagnosis of Feline Immunodeficiency. Veterinary Sciences. 2025. DOI: https://doi.org/10.3390/vetsci12020089

[18] Gao S, Du J, Tian Z, Niu Q, Huang D, Wang J, et al.. A SYBR green I–based quantitative RT-PCR assay for bovine ephemeral fever virus and its utility for evaluating viral kinetics in cattle. Journal of Veterinary Diagnostic Investigation. 2019. DOI: https://doi.org/10.1177/1040638719895460

[19] Simanova I, Alekseyenkova SV, Yurov K. Molecular-genetic analysis of bovine herpesvirus-5 (BoHV-5) in the milk of cows in farms of Vologda region. IOP Conference Series: Earth and Environment. 2020. DOI: https://doi.org/10.1088/1755-1315/548/7/072042

[20] Parreño V, López MV, Rodriguez D, Vena M, Izuel M, Filippi J, et al.. Development and statistical validation of a guinea pig model for vaccine potency testing against Infectious Bovine Rhinothracheitis (IBR) virus. Vaccine. 2010. DOI: https://doi.org/10.1016/j.vaccine.2010.01.035

[21] Breitschwerdt E, Broadhurst J, Cherry NA. Bartonella henselae as a cause of acute-onset febrile illness in cats. JFMS open reports. 2015. DOI: https://doi.org/10.1177/2055116915600454

[22] Tembo NFP, Muma JB, Hang'ombe B, Munyeme M. Clustering and spatial heterogeneity of bovine tuberculosis at the livestock/wildlife interface areas in Namwala District of Zambia. Veterinary World. 2020. DOI: https://doi.org/10.14202/vetworld.2020.478-488

[23] Brenner J, Oura C, Asis I, Maan S, Elad D, Maan N, et al.. Multiple Serotypes of Bluetongue Virus in Sheep and Cattle, Israel. Emerging Infectious Diseases. 2010. DOI: https://doi.org/10.3201/eid1612.100239

[24] Sang R, Murithi M, Kasiiti J, Owange N, Macharia P, Arum S, et al.. Tracking the inter-epidemic activity of Rift Valley fever (RVFV) virus in RVF outbreak hotspots in Kenya: Determination of biotic and socio-economic drivers. International Journal of Infectious Diseases. 2014. DOI: https://doi.org/10.1016/J.IJID.2014.03.791

[25] Takai S, Mizuno Y, Suzuki Y, Sasaki Y, Kakuda T, Kirikae T. [Rhodococcus equi infections in humans: an emerging zoonotic pathogen].. Nihon saikingaku zasshi. Japanese journal of bacteriology. 2024. DOI: https://doi.org/10.3412/jsb.79.15

[26] Bree L, Bergamino C, Mullins RA, Kelly P, Shiel R. Periaortic lymphoma in a cat. JFMS open reports. 2017. DOI: https://doi.org/10.1177/2055116917729627

[27] Lavrentiev I, Igolkin A, Shevtsov A, Kolbin I, Puzankova O, Gavrilova VL, et al.. Virucidal activity of disinfectants against African swine fever virus. Veterinary Science Today. 2025. DOI: https://doi.org/10.29326/2304-196x-2025-14-2-156-163